Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced the completion of enrollment in its THUNDER ...

US-based Penumbra has completed enrolment for the THUNDER Investigational Device Exemption study of its advanced thrombectomy ...

Wells Fargo notes that Clinicaltrials.gov lists Penumbra’s THUNDER trial as having reduced the total enrollment number to 216 from 275 as of October 16, so when Penumbra announc ...

Penumbra, Inc. announced the completion of enrollment in its THUNDER clinical study for patients with acute ischemic stroke. TH ...

Needham analyst Michael Matson has maintained their neutral stance on PEN stock, giving a Hold rating on October 21. Michael Matson has given ...

The long-standing debate as to when to start anticoagulation in patients with an acute ischemic stroke and atrial ...

News about one of Penumbra's (NYSE: PEN) development programs and an analyst's price target raise combined to boost the medical device company's stock on Monday. Its price rose by over 4% ...

In its 48 years of presenting theater works rooted in the experiences of African-Americans, Penumbra Theatre’s linchpin relationship has been with playwright August Wilson. But the company has ...

On Friday, Penumbra Inc . (NYSE:PEN), a global healthcare company, saw its price target increased by Piper Sandler from $220.00 to $225.00. The firm maintained an Overweight rating on the stock ...